Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(15):1121-1123; doi:10.1093/jnci/94.15.1121
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Twombly, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Twombly, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 15, 1121-1123, August 7, 2002
© 2002 Oxford University Press

NEWS

Task Force Urges Doctors to Discuss Breast Cancer Prevention

Renee Twombly

The first 10% of the full text of this article appears below.

A federal panel’s review of research on the ability of tamoxifen to prevent the development of breast cancer suggests that the biggest limitation on the use of the drug for this purpose is that primary care physicians are not talking with their patients about whether the agent is right for them.

When used in high-risk patients, two selective estrogen receptor modulators (tamoxifen and raloxifene) can cut the risk of invasive estrogen receptor-positive breast cancer in half, said the U.S. Preventive Services Task Force (USPSTF) in their July 2 Annals of Internal Medicine report and associated clinical guidelines.

But that is only if the drugs—and specifically tamoxifen, which is FDA approved for prevention of breast cancer—are actually used. The task force report, underscoring an apparent reluctance of primary . . . [Full Text of this Article]

Validating Chemoprevention

Preventive Medicine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?